key: cord-0765369-l6ba8tz6 authors: Witting, Celeste; Quaggin-Smith, Jessica; Mylvaganam, Ruben; Peigh, Graham; Angarone, Michael; Flaherty, James D. title: Invasive Pulmonary Aspergillosis After Treatment with Tocilizumab in a Patient with COVID-19 ARDS: A Case Report date: 2020-11-20 journal: Diagn Microbiol Infect Dis DOI: 10.1016/j.diagmicrobio.2020.115272 sha: df3bddc3ac45906533cb160add2f9668cbf90a89 doc_id: 765369 cord_uid: l6ba8tz6 Tocilizumab, an IL-6 receptor antagonist, has been used to treat critically ill patients with Coronavirus Disease-2019 (COVID-19). We present the case of a previously immunocompetent man with COVID-19 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy. Tocilizumab, an IL-6 receptor antagonist, has been used to treat critically ill patients with Coronavirus Disease-2019 . We present the case of a previously immunocompetent man with COVID-19 who developed invasive pulmonary aspergillosis after treatment with tocilizumab, illustrating the importance of considering opportunistic infections when providing immune modulating therapy. Coronavirus-2 (SARS-CoV-2), has emerged as a global pandemic that has affected millions. Severe presentations of COVID-19, characterized by significant pulmonary disease and shock, are likely propagated by both direct viral effects and a cytokine-mediated inflammatory response, or "cytokine storm." 1 Interleukin-6 (IL-6) plays a central role in the cytokine storm that is common in severe cases of COVID-19. 2 Accordingly, IL-6 receptor antagonists such as tocilizumab, typically used in the treatment of rheumatoid arthritis (RA), have been used in select cases of COVID-19 to suppress the suspected inflammatory damage. 1 Select governmental health organizations have recommended tocilizumab for patients with extensive and bilateral lung disease. 3 Initial data on the use of these agents has been promising. Tocilizumab decreases inflammation in COVID patients, as measured with both fever and serum inflammatory markers such as C-reactive protein (CRP). 4 Additionally, a small Chinese preprint study of patients with severe COVID-19 reported 75% had reduced oxygen requirement, 90% had improved computed tomography (CT) scans, and, notably, there were no reports of secondary infections or clinical deterioration. 1 Although initial data for tocilizumab in COVID-19 is promising, there are risks to immune modulating therapies, especially the development of opportunistic infections. 5 Tocilizumab has been associated with invasive fungal infections including invasive candidiasis, Pneumocystis, and Cryptococcal pneumonia. 6, 7 This risk is doubled compared to controls. 8 This case report presents a patient with severe COVID-19 pneumonia who developed invasive pulmonary aspergillosis (IPA) after treatment with tocilizumab. A 72-year-old man with a 30 pack-year smoking history and a predilection for gardening presented with cough and fever. His chest X-ray (CXR) showed bilateral opacifications and nasopharyngeal polymerase chain reaction was positive for SARS-CoV2 when sent to the state's public health department. Three days after admission, he developed acute hypoxemic respiratory failure, was transferred to the intensive care unit (ICU), and mechanically ventilated. Despite lung protective ventilation, empiric treatment for hospital acquired pneumonia Figure 2 ). After initiation of dual therapy voriconazole and micafungin, the patient had improvement in his oxygenation and BAL results, but remained ventilator dependent and eventually received a tracheostomy. Since initial submission of this report, the patient was decannulated (day 69) and discharged (day 80), and has recovered well at home with physical therapy. In this case, we describe new onset invasive fungal infection after treatment with tocilizumab in a patient with acute hypoxemic respiratory failure secondary to COVID-19. Immune modulating agents are known to be a major risk factor for IPA. 9 Immunosuppressive drugs such as steroids are occasionally used to treat severe H1N1 infections, and they are strongly associated with IPA. 10 Ultimately, the risk of invasive fungal infections with tocilizumab treatment is incompletely understood, in part because fungal infections are generally rare compared to other opportunistic infections, and the scientific community is still collecting data about many monoclonal antibody treatments. 5 The risk of IPA is most wellestablished with the older TNF-alpha inhibitors, but newer biologics are now being implicated as well. 11 All patients who receive tocilizumab are recommended to be tested for latent tuberculosis, 12 but there are not yet standardized recommendations for screening for other opportunistic infections. It appears that patients with severe COVID-19 are at increased risk for IPA, even without the use of immune suppressing medication. Recent preprint research suggests that critically ill patients with COVID-19 are at high risk for IPA even without tocilizumab or other immune modulating medication. 13, 14 This phenomenon is also seen in severe H1N1influenza infections, as prior work has shown that H1N1-associated IPA occurs in up to 28% of patients in the ICU, and carries a mortality of 61%. 15, 16 Although it is possible that our patient would have developed IPA despite tocilizumab treatment, COVID-and H1N1-associated IPA both tend to appear at a mean of 3 days after intubation. 13, 16 Our patient's deterioration and diagnosis of IPA occurred on day 13, suggesting an alternate etiology of the fungal infection. While the causality of tocilizumab with our patient's IPA is speculative as there was no fungal culture on the BAL prior to tocilizumab administration, there is a known association between immune modulating medications and opportunistic respiratory infections including IPA. [6] [7] [8] It is therefore important to consider de novo opportunistic infections prior to initiating treatment with tocilizumab. Additionally, clinical deterioration after starting such an immune modulating agent warrants investigation for an opportunistic infection; early identification and prompt administration of antifungals improves survival in IPA. 12 Because critically ill patients in the ICU are already at increased risk for IPA, 9 prior to the administration of immunomodulatory agents for severe cases of COVID-19, appropriate patients should be evaluated for latent fungal infections (e.g. cultures, serologic testing, galactomannan). It is also wise to consider other risk factors that would make a patient prone to invasive fungal infections, such as underlying immune compromise (i.e. malignancy, chemotherapy, transplant patients) as well as patients with organ dysfunction (i.e. pulmonary disease, renal or liver failure). 9 Although the causal link between agents like tocilizumab and invasive fungal infections remains unclear, this case illustrates the importance of maintaining a high degree of clinical suspicion for opportunistic infections when treating COVID-19 patients with immune modulating therapy. Effective treatment of severe COVID-19 patients with Tocilizumab The cytokine release syndrome (CRS) of severe COVID-1 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality General Office of the National Health Commission (China) Tocilizumab treatment in COVID-19: A single center experience Fungal infections and new biologic therapies Integrated safety in tocilizumab clinical trials Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab Clinical risk factors for invasive aspergillosis Invasive pulmonary aspergillosis in patients with influenza infection: A retrospective study and review of the literature Aspergillosis in patients treated with monoclonal antibodies High prevalence of putative invasive pulmonary aspergillosis in critically ill COVID-19 patients Fatal invasive aspergillosis and Coronavirus disease in an immunocompetent patient Invasive pulmonary aspergillosis complicating severe influenza: Epidemiology, diagnosis and treatment Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: A retrospective study